Living with kidney disease often means dealing with anemia, a condition where the body lacks enough healthy red blood cells. For adults on peritoneal dialysis, finding the right treatment to manage these blood levels is a constant challenge. A recent look at data from over 1,600 patients compared two different approaches: roxadustat-based regimens and those using erythropoiesis-stimulating agents (ESAs).
The analysis found that patients using roxadustat had significantly higher average hemoglobin levels after treatment. Specifically, the roxadustat group saw a mean increase of 7.30 g/L. Additionally, the data showed a lower rate of adverse events for those on roxadustat compared to those on standard ESA treatments.
While these results are promising, the evidence is still early. The researchers noted that the data for many secondary outcomes, like red blood cell counts, were inconsistent. Because the different treatment plans were not uniform and some safety data wasn't standardized, it is currently too early to say if roxadustat is definitively better than standard care. Talk to your doctor to see which option fits your specific needs.
Common questions
How does roxadustat compare to standard ESA treatments for anemia?
In a study of 1,636 adults on peritoneal dialysis, those using roxadustat-based regimens had higher average post-treatment hemoglobin levels than those on ESA-based regimens. Specifically, the roxadustat group saw a mean difference of 7.30 g/L. However, because the comparison groups were not uniform, more research is needed to determine if it is clinically superior.
Is roxadustat safer than other treatments for kidney patients?
The data showed a lower rate of adverse events for patients using roxadustat compared to those on ESA-based regimens. However, the researchers noted that the way these events were defined and tracked was not standardized across the study, so the results should be viewed with caution.
What are the limitations of this finding?
The evidence for many secondary outcomes, like red blood cell counts and lipid levels, was inconsistent or not enough to be certain. Because the treatment plans were not uniform and some safety data was not standardized, there is currently not enough evidence to confirm if roxadustat is superior to standard care.
